About Serine/threonine-protein kinase pim-1
Serine/threonine-protein kinase pim-1 (PIM1) is a protein
from Homo sapiens identified by UniProt accession
P11309, 313 residues long.
MolForge cross-references it against 0 known binders and
335 disease associations.
Target properties
| Protein name | Serine/threonine-protein kinase pim-1 |
| UniProt accession | P11309 |
| Gene | PIM1 |
| Organism | Homo sapiens |
| Length | 313 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (8)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (335)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- diffuse large B-cell lymphoma · score 0.47
- mean corpuscular volume · score 0.46
- multiple myeloma · score 0.45
- lymphoid neoplasm · score 0.43
- mean corpuscular hemoglobin · score 0.42
- mean reticulocyte volume · score 0.39
- Central Nervous System Lymphoma · score 0.38
- Red cell distribution width · score 0.38
- erythrocyte count · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P11309-F1 | alphafold | PREDICTED | 89.43 | — |
Amino-acid sequence (313 residues)
MLLSKINSLA HLRAAPCNDL HATKLAPGKE KEPLESQYQV GPLLGSGGFG SVYSGIRVSD NLPVAIKHVE KDRISDWGEL PNGTRVPMEV VLLKKVSSGF SGVIRLLDWF ERPDSFVLIL ERPEPVQDLF DFITERGALQ EELARSFFWQ VLEAVRHCHN CGVLHRDIKD ENILIDLNRG ELKLIDFGSG ALLKDTVYTD FDGTRVYSPP EWIRYHRYHG RSAAVWSLGI LLYDMVCGDI PFEHDEEIIR GQVFFRQRVS SECQHLIRWC LALRPSDRPT FEEIQNHPWM QDVLLPQETA EIHLHSLSPG PSK
Explore Serine/threonine-protein kinase pim-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets